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Poster Session I S269Results:HLA-DP (A1 or B1) mismatch compared to DP match did
not affect the incidences of acute graft-versus-host disease (GVHD)
grades II-IV (33% vs. 27%; P5 0.20), or grades III-IV (6% vs. 8%; P
5 0.87). Furthermore, the incidence of chronic GVHD was similar
(28% vs. 27%; P5 0.49), and there was no impact on patient overall
survival using DP mismatched compared to DP matched donors
(55% vs. 50%, P 5 0.72). However, in separate analysis DPA1 mis-
match was associated with decreased overall survival (HR 1.50, P 5
0.02), when compared to matched recipients irrespective of
HLA-DPB1 and HLA-C match. In univariate analysis, HLA-
DPA1 mismatch was associated with increased risk of transplant-
related mortality (P 5 0.04), although incidences of acute and
chronic GVHD were similar. Furthermore, a tendency to an in-
creased risk of infection-related mortality was noted in patients
mismatched for HLA-DPA1 (P 5 0.07).
Conclusions: This study suggests that HLA-DPA1 mismatch is
associated with inferior survival, which may be caused by an in-
creased risk of infection-related mortality. At present there are
few publications available, which investigate the role of DPA1
and DPB1 mismatch separately, and future studies to uncover
the importance of DPA1 and DPB1 compatibility in unrelated
HSCT are warranted.177
ETHNICITY BETWEEN DONOR AND RECIPIENT AFFECTS OVERALL
SURVIVAL IN UMBILICAL CORD BLOOD TRANSPLANTATION
Bachier, C., Cheruku, P.S., Shaughnessy, P., Chan, K., Madden, R.,
Jude, V., LeMaistre, C.F. Texas Transplant Institute, San Antonio, TX
This study retrospectively analyses the effects of ethnicity on
clinical outcomes after UCBT. Patients were transplanted at
the Texas Transplant Institute in San Antonio between 2001
and 2010. CIBMTR and hospital records supplied the data.
Two hundred and sixty patients were evaluated including Whites
(76), Hispanics (141), Blacks (19) and Asians (6). Black and Asians
were excluded from analysis due to small numbers. Age, cell
dose, myeloablative versus non-myeloablative conditioning regi-
mens, single (s) versus double (d) UCBT and the prevalence of
high risk malignancies were similar between the two ethnicities
(Table). More Whites (88%) were transplanted for malignant
diseases than Hispanics (68%) (p\0.001). Incidence of acute
and chronic graft-versus-host disease (GVHD) (Table), overall
survival (OS) (Table), disease related mortality (DRM) and
non-disease related mortality (NDRM) were similar between
Whites (DRM: 20% and NDRM: 23%) and Hispanics (DRM:
16% and NDRM: 24%) and regardless of whether they had ma-
lignant or non-malignant disease, standard or high risk malignant
disease, single or double transplants, and age. Hispanics who re-
ceived an ethnically matched s UCB product had a longer OS
(88.7 months) than Whites (68.5 months) (p 5 0.030) and
a shorter OS (43.3 months) than Whites when each received an
ethnically mismatched s UCB product (p 5 0.004). White and
Hispanics with ethnically matched and mismatched sUCBT
had similar number of patients with malignant and high risk
malignant disease.
Improvement in OS in Hispanics patients with ethnically
matched s UCB products was related to an increase in OS from
transplant related mortalities while worse OS in Hispanics with
ethnically mismatched s UCB products was related to decreases
in OS from both transplant-related and disease-related mortalities.
Cell dose and degree of HLA matching was similar for all patients
and for Whites and Hispanics with ethnically matched and mis-
matched s UCB. There was a trend to shorter OS among all pa-
tients with ethnically matched (82.3 months) versus mismatched
(68.5 months) s UCB. OS was shorter among all Hispanics with
mismatched (43.3 months) than matched (88.7 months) s UCBT
(p 5 0.001).
In conclusion, ethnicmismatches between donor and recipient ap-
pear to affect survival in s UCBT. The effect of ethnic mismatches
was more pronounced in Hispanics than Whites.Table.
Characteristics and Outcomes White HispanicNumber of patients 76 141Median age at transplant, years
(range)9.0 (0.1-79.2) 8.0 (0.1-61.7)Age category<18 61 (82%) 116 (82%)$18 13 (17%) 21 (15%)Median weight, kg (range) 25 (4-111) 26.3 (4-160)Recipient sexmale 43 (57%) 90 (65%)female 31 (41%) 50 (35%)Transplant typesingle 57 (75%) 107 (76%)double 18 (24%) 34 (24%)Recipient CMV statuspostitive 24 (32%) 61 (43%)negative 27 (36%) 41 (29%)*Malignant disease 66(88%) 96 (68%)Ethnicity match for s UCBconcordant 39 (70%) 57 (53%)discordant 10 (18%) 28 (26%)*HLA-matching, single transplants6(6) 14 (25%) 9 (8%)5(6) 28 (56%) 50 (47%)4(6) 13 (23%) 44 (41%)Median cell dosex107 TNC/kg (range) 5.7 (1.5-28.5) 5.6 (1.5-45.5)Median days ANC >500 21 (10-50) 20 (10-100)Median days platelets >20K 51 (24-165) 47 (21-167)Median days platelets >50K 60 (29-137) 49 (24-224)Grade of acute GVHDgrades II - IV 33 (44%) 48 (34%)grades III - IV 11 (15%) 31 (22%)Chronic GVHDlimited 9% 28%extensive 11% 15%Overall survival (months) 70.2 73.7Median follow-up in months (range) 28 (.25-121) 25 (.25-69)*p-value <0.05
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GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER DOUBLE-UNIT CORD
BLOOD TRANSPLANTATION (DCBT) IS ASSOCIATEDWITH UNIQUE CLIN-
ICAL FEATURES INCLUDING A HIGHER INCIDENCE OF GRADE III-IV
ACUTE GVHD (AGVHD) IN CHILDREN
Ponce, D.M.1, Gonzales, A.M.R.1, Lubin,M.N.1, Castro-Malaspina, H.1,
Geralt, S.A.1, Goldberg, J.D.1, Jakubowski, A.A.1, Papadopoulos, E.B.1,
Perales, M.-A.1, van den Brink, M.R.M.1, Young, J.W.1,
Kernan, N.A.2, O’Reilly, R.J.2, Prockop, S.E.2, Scaradavou, A.2,
Stevens, C.E.1, Barker, J.N.1 1Memorial Sloan-Kettering Cancer Center,
NewYork,NY; 2Memorial Sloan-Kettering Cancer Center, NewYork, NY
GVHD is a serious complication and common cause of transplant-
related mortality after DCBT. However, relatively little is known
about DCBT GVHD manifestations, treatment response, and risk
factors. We evaluated 108 DCBT recipients (median 37 years, range
0.9-69) transplanted for high-risk hematologic malignancies with
myeloablative (n5 81) or non-myeloablative (n5 27) conditioning,
4-6/6 HLA-matched grafts, calcineurin-inhibitor/mycophenolate
mofetil, and no ATG. With a median follow-up of 28 months, the
cumulative incidences of day 180 grade II-IV and III-IV aGVHD
were 52% (95%CI:42-62) and 24% (95%CI:15-32), respectively.
The median onset was 40 days (range 14-161), and the gut was
most commonly affected (43/54, 80%). Twenty-five patients with
mainly grade II gut aGVHD were treated with budesonide alone,
26 patients with predominantly grade III-IV aGVHD received sys-
temic corticosteroids, and treatment response was achieved in over
80% by day 56 of therapy. However, 41 patients had active
GVHD after day 100 with the majority (61%) having aGVHD,
particularly of the gut. Classical chronic GVHD was uncommon.
S270 Poster Session IUnivariate analysis of the association between patient/graft charac-
teristics and grade III-IV aGVHD showed the only significant factor
associated with a higher severe aGVHD incidence was age 0-15
years. Multivariate Cox regression analysis was performed (Table).
Younger age was independently associated with a higher severe
aGVHD incidence whereas better engrafting unit-recipient 8-9/10
HLA-allele match was protective. There was a trend toward better
unit-unit HLA-match being associated with worse aGVHD, but,
surprisingly, total infused TNC/kg had no relationship. The 2-
year PFS of 72% (95%CI:51-94) in children was higher than the
56% (95%CI:45-66) in adults despite their greater incidence of se-
vere aGVHD. We conclude that aGVHD after DCBT is common,
predominantly affects the gut, has a high treatment response, chil-
dren are at a higher risk for severe disease, and late GVHD fre-
quently has acute features. While survival is promising, improved
prophylaxis and treatment are needed. A possible approach to reduce
aGVHD in pediatric DCBT recipients with adequate CB unit doses
would be to prioritize high resolution HLA-match. Moreover, our
data does not currently support an upper limit of infused TNC/kg
in DCBT recipients. Further investigation of the biology underlying
these unique observations should be a priority.
Table. Multivariate Analysis
Cumulative
Characteristic Incidence (95% CI) Hazard Ratio P ValueAge (years)
0-15 (n 5 18) 41% (17-65) 2.6 (1.0-6.4) 0.042
$ 16 (n 5 90) 20% (12 -29) Reference -
Engrafting Unit-Recipient 10 Allele HLA-Match
2-7/10 (n 5 83) 27% (17-37) Reference -
8-9/10 (n 5 25) 12% (0-25) 0.3 (0.1-1.0) 0.053
Unit-Unit 10 Allele HLA-Match
0-5/10 (n 5 59) 20% (9-29) Reference -
6-10/10 (n 5 49) 29% (16-42) 2.2 (1.0-5.0) 0.062
Total TNC x107/kg
< 5.0 (n 5 68) 20% (10-29) Reference -
$ 5.0 (n 5 40) 31% (16-46) 1.2 (0.5-2.8) 0.617179
DOUBLE-UNIT CORD BLOOD TRANSPLANTATION (DCBT) FOR ACUTE
LEUKEMIA: HIGH DISEASE-FREE SURVIVAL IN ADULTS AND CHILDREN
WITH COMPARABLE SURVIVAL IN EUROPEAN AND MINORITY PATIENTS
Barker, J.N.1, Ponce, D.M.1, Gonzales, A.M.R.1, Lubin, M.N.1, Castro-
Malaspina, H.1, Giralt, S.A.1, Goldberg, J.D.1, Jakubowski, A.A.1,
Koehne, G.1, Papadopoulos, E.B.1, Perales, M.-A.1, Sauter, C.S.1, van
den Brink, M.R.M.1, Young, J.W.1, Boulad, F.2, Kobos, R.2,
O’Reilly, R.J.2, Prockop, S.E.2, Small, T.N.2, Stevens, C.E.1,
Kernan, N.A.2, Scaradavou, A.2 1Memorial Sloan-Kettering Cancer Cen-
ter, New York, NY; 2Memorial Sloan-Kettering Cancer Center, New
York, NY
As DCBT may improve engraftment and protect against relapse,
we have adopted DCBT for children and adults with high-risk acute
leukemia, myelodysplasia (MDS), and myeloproliferative diseases
(MPD). We analyzed DFS in 75 DCBT recipients with acute leuke-
mia in morphologic remission or aplasia (n 5 69), and MDS/MPD
with # 5% blasts (n 5 6) transplanted 10/2005-4/2011. Children
(n5 23, 43% AML, 52% ALL, and 4%MDS/MPD) were a median
of 9 years (range 0.9-15) and 37 kg (range 7-72), 30% were
European, and 26% were CMV sero-positive. All received high-
dose conditioning. Pediatric grafts had a median infused TNC x
107/kg of 3.3 (larger unit) and 2.6 (smaller unit), and 2% of units
were 6/6 HLA-A,-B antigen,-DRB1 allele matched, 63% 5/6, and
35% 4/6. Adults (n 5 52, 63% AML, 27% ALL, and 10% MDS/
MPD) were a median of 41 years (range 16-69) and 69 kg (range
47-105), 48% were European, and 69% were CMV sero-positive.
Fifty percent received high-dose and 50% reduced intensity condi-
tioning. Their units had median infused TNC/kg of 2.7 and 1.9,
and 3%were 6/6HLA-matched, 47% 5/6, and 50% 4/6. All patients
received calcineurin-inhibitor/ mycophenolate mofetil immunosup-
pression. Sustained neutrophil engraftment was seen in 91% of chil-
dren and 94% of adults at medians of 20 and 26 days, respectively.
Day 180 grade II-IV acute GVHD incidence was 44% in childrenand 58% in adults. Day 100 transplant-related mortality was 9% in
children and 19% in adults. 2-year relapse incidence was 9% in chil-
dren and 6% in adults. With a median survivor follow-up of 26
months (range 4-70), 2-year DFS was 78% in children and 64% in
adults. Univariate analysis of variables potentially influencing 2-
year DFS is shown (Table). There were no differences in 2-year
DFS according to ancestry, remission status, conditioning intensity,
engrafting unit infused TNC dose/kg, or engrafting unit-recipient
HLA-match (4-6/6 or 10 allele). However, CMV seronegative pa-
tients had a higher 2-year DFS (85% vs 55%, p 5 0.018). Multivar-
iate analysis revealed CMV serostatus was a DFS predictor
independent of patient age. We have previously shown that DCBT
extends transplant access to minorities. We now demonstrate that
DCBT can achieve high and comparable DFS in European and
non-European pediatric and adult leukemia patients. Our findings
support DCBT as an immediate alternative for high-risk acute leu-
kemia patients without rapidly available unrelated donors, especially
given the very low relapse incidence.
Table.
Comparison 2-Year DFS P ValueAncestry Europeans (n 5 32) 67% 0.884
Non-Europeans (n 5 43) 69%Remission CR1 (n 5 41) 69% 0.663
Status All others (n 5 34) 67%
Conditioning High-dose (n 5 49) 71% 0.687
Intensity Reduced intensity (n 5 26) 62%
Recipient CMV CMV+ (n 5 42) 55% 0.018
Sero-status CMV- (n 5 33) 85%
Engrafting Unit < 3.0 x 107/kg (n 5 56) 65% 0.307
Infused TNC Dose $ 3.0 x 107/kg (n 5 19) 77%
Engrafting Unit-recipient 4/6 (n 5 30) 72% 0.596
Match (4-6/6) 5-6/6 (n 5 45) 65%
Engrafting Unit-recipient 2-6/10 (n 5 41) 64% 0.418
Match (10 allele) 7-9/10 (n 5 34) 73%180
A/B ONLY TYPED DONORS: POSSIBLE BUT IMPROBABLE 6/6 HLA ALLELE
MATCHES
Dehn, J.1, Maus, T.1, Buck, K.1, Hermanson, J.1, Beraun-Salchert, Y.1,
Wood, J.1, Hsu, S.2 1National Marrow Donor Program, Minneapolis,
MN; 2ARC-Penn Jersey Region, Philadelphia, PA
Background: Patients searching the Be The Match Registry are
evaluated for HLA matching with over 9.5 million donors, 88% with
a minimum of HLA-A/B/DRB1 typing and 12% with HLA-A/B
only (i.e., noDRB1) typing. Patients with no potential 6/6 HLA allele
matched donors present a challenging search for which transplant
centers may consider DRB1 typing of A/B only donors. Selection of
A/B only donor typing varies by center, so a study was performed to
evaluate the utility of this practice in identifying A/B/DRB1 (6/6)
matched donors given the size of the Be The Match Registry.
Methods:We identified 180 new patient searches with no potential
6/6 HLA allele matched donors, reviewed the search results, and
typed DRB1 on a total of 2,976 A/B only donors with stored DNA
samples. The median number of tested A/B only donors per patient
was 4, ranging from 1 to 231. Donor DRB1 typing results were com-
pared to the corresponding patient’s DRB1 alleles to confirm high
resolution match status.
Results: Of 2,976 donors typed for 180 patients, two donors
matched their respective patient’s DRB1 typing. One DRB1
matched donor became a 10/10 match to the patient whose search
previously contained no 6/6 potential matches. This donor carried
an A/B/DRB1 phenotype that had not previously been identified his-
torically in a Be The Match Registry donor.
Conclusions: These results show very limited benefit to HLA-A/B
only donor testing for the patients considered in this study, with only
two patients identifying a DRB1 matched donor. With most A/B
only donors typed by serology, additional mismatches are possible.
Since only donors with stored DNA samples were tested (26% of
the total A/B only donors), additional DRB1 matches may have
been identified if every A/B only donor for each patient were tested.
Study patients represented challenging searches with no potential
